Clinical trial · Interventional
Automatized "Semi-Whole-Body"-MRI Protocol for Cancer Staging
Evaluation of an Innovative Automatized "Semi-Whole-Body"-MRI Protocol to Increase Patient Comfort and Cost-effectiveness of Oncologic Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient recruitment
Summary
Brief summary (as posted)
The aims of this study are * to evaluate the image quality and robustness of a whole-body MRI protocol by using an innovative partially automatic algorithm (DOT engine), that automatically optimizes protocol parameters depending on body region (e.g. thorax versus abdomen) * to compare lesion detectability between wb-MRI and the gold standard positron emission tomography (PET)/CT * to compare patient comfort between PET/CT and wb-MRI using a dedicated questionnaire * to compare duration of image acquisition with regards to cost-effectiveness
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Semi whole-body MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Oncologic patients
- description
- Oncologic patients with a previous PET/CT for whole-body staging
- interventionNames
- Diagnostic Test: Semi whole-body MRI
Primary outcomes (1)
- measure
- to compare lesion detectability between wb-MRI and the gold standard PET/CT
- timeFrame
- 30 minutes duration of study-related MRI protocol
- description
- \- Primary outcome will be the organ based malignant lesion detectability (Thorax, Abdomen). This will be quantified as a dichotomous variable (present/absent) for MRI and PET/CT. Outcome will be based on two board certified radiologists. In case of disagreement, consensus will be taken. Results will be obtained in a single reading after inclusion of 50 patients. Readers will be blinded to clinical patient data and results of PET/CT.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically indicated PET/CT for cancer staging or response assess-ment in patients with histopathologically confirmed solid tumors (e.g.prostate, breast, gastrointestinal, testicles) * MRI can be scheduled within 1 week to PET/CT exam Exclusion Criteria: * general MRI contraindications (devices (e.g. certain pacemakers), pregnancy, claustrophobia) * severely reduced general condition * impaired renal function
References
Publications (0)
Data not yet available